BioNTech Bags Fast-Track Status for Melanoma Treatment

BioNTech is on the Fast Track. In an announcement this morning, the company said the U.S. Food and Drug Administration (FDA) gave its cancer immunotherapy candidate, BNT111, a Fast Track Designation.